Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 21421818)

1.

Dysfunctional ryanodine receptor and cardiac hypertrophy: role of signaling molecules.

Yamaguchi N, Chakraborty A, Pasek DA, Molkentin JD, Meissner G.

Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H2187-95. doi: 10.1152/ajpheart.00719.2010. Epub 2011 Mar 18.

2.

Cardiac hypertrophy associated with impaired regulation of cardiac ryanodine receptor by calmodulin and S100A1.

Yamaguchi N, Chakraborty A, Huang TQ, Xu L, Gomez AC, Pasek DA, Meissner G.

Am J Physiol Heart Circ Physiol. 2013 Jul 1;305(1):H86-94. doi: 10.1152/ajpheart.00144.2013. Epub 2013 May 10.

3.

Ryanodine receptor type 2 is required for the development of pressure overload-induced cardiac hypertrophy.

Zou Y, Liang Y, Gong H, Zhou N, Ma H, Guan A, Sun A, Wang P, Niu Y, Jiang H, Takano H, Toko H, Yao A, Takeshima H, Akazawa H, Shiojima I, Wang Y, Komuro I, Ge J.

Hypertension. 2011 Dec;58(6):1099-110. doi: 10.1161/HYPERTENSIONAHA.111.173500. Epub 2011 Oct 10.

4.

Early cardiac hypertrophy in mice with impaired calmodulin regulation of cardiac muscle Ca release channel.

Yamaguchi N, Takahashi N, Xu L, Smithies O, Meissner G.

J Clin Invest. 2007 May;117(5):1344-53. Epub 2007 Apr 12.

5.

FKBP12.6 mice display temporal gender differences in cardiac Ca(2+)-signalling phenotype upon chronic pressure overload.

Prévilon M, Pezet M, Semprez F, Mercadier JJ, Rouet-Benzineb P.

Can J Physiol Pharmacol. 2011 Nov;89(11):769-82. doi: 10.1139/Y11-075. Epub 2011 Oct 18.

PMID:
22007848
6.

Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.

Nakamura TY, Iwata Y, Arai Y, Komamura K, Wakabayashi S.

Circ Res. 2008 Oct 10;103(8):891-9. doi: 10.1161/CIRCRESAHA.108.175141. Epub 2008 Sep 5.

7.

Inhibition of CaMKII does not attenuate cardiac hypertrophy in mice with dysfunctional ryanodine receptor.

Chakraborty A, Pasek DA, Huang TQ, Gomez AC, Yamaguchi N, Anderson ME, Meissner G.

PLoS One. 2014 Aug 5;9(8):e104338. doi: 10.1371/journal.pone.0104338. eCollection 2014.

9.

Accelerated development of pressure overload-induced cardiac hypertrophy and dysfunction in an RyR2-R176Q knockin mouse model.

van Oort RJ, Respress JL, Li N, Reynolds C, De Almeida AC, Skapura DG, De Windt LJ, Wehrens XH.

Hypertension. 2010 Apr;55(4):932-8. doi: 10.1161/HYPERTENSIONAHA.109.146449. Epub 2010 Feb 15.

10.

Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.

Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, Molkentin JD, Drexler H, Wollert KC.

Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11363-8. Epub 2002 Aug 12.

11.

Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice.

Oliveira RS, Ferreira JC, Gomes ER, Paixão NA, Rolim NP, Medeiros A, Guatimosim S, Brum PC.

J Physiol. 2009 Aug 1;587(Pt 15):3899-910. doi: 10.1113/jphysiol.2009.173948. Epub 2009 Jun 8.

12.

Polycystin-1 activates the calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway.

Puri S, Magenheimer BS, Maser RL, Ryan EM, Zien CA, Walker DD, Wallace DP, Hempson SJ, Calvet JP.

J Biol Chem. 2004 Dec 31;279(53):55455-64. Epub 2004 Oct 5.

13.

Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo.

Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, Richardson JA, Hill JA, Olson EN.

Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):907-12. Epub 2002 Jan 8.

14.

Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.

Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD.

Circ Res. 2004 Jan 9;94(1):110-8. Epub 2003 Dec 1.

15.

Cardiac calcium signalling pathologies associated with defective calmodulin regulation of type 2 ryanodine receptor.

Arnáiz-Cot JJ, Damon BJ, Zhang XH, Cleemann L, Yamaguchi N, Meissner G, Morad M.

J Physiol. 2013 Sep 1;591(Pt 17):4287-99. doi: 10.1113/jphysiol.2013.256123. Epub 2013 Jul 8.

16.

Cardiac CaM Kinase II genes δ and γ contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy.

Kreusser MM, Lehmann LH, Keranov S, Hoting MO, Oehl U, Kohlhaas M, Reil JC, Neumann K, Schneider MD, Hill JA, Dobrev D, Maack C, Maier LS, Gröne HJ, Katus HA, Olson EN, Backs J.

Circulation. 2014 Oct 7;130(15):1262-73. doi: 10.1161/CIRCULATIONAHA.114.006185. Epub 2014 Aug 14.

17.

Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.

Braz JC, Bueno OF, Liang Q, Wilkins BJ, Dai YS, Parsons S, Braunwart J, Glascock BJ, Klevitsky R, Kimball TF, Hewett TE, Molkentin JD.

J Clin Invest. 2003 May;111(10):1475-86.

18.

Overexpression of CaMKIIδc in RyR2R4496C+/- knock-in mice leads to altered intracellular Ca2+ handling and increased mortality.

Dybkova N, Sedej S, Napolitano C, Neef S, Rokita AG, Hünlich M, Brown JH, Kockskämper J, Priori SG, Pieske B, Maier LS.

J Am Coll Cardiol. 2011 Jan 25;57(4):469-79. doi: 10.1016/j.jacc.2010.08.639.

19.
20.

Ca2+/calmodulin-dependent protein kinase II and protein kinase A differentially regulate sarcoplasmic reticulum Ca2+ leak in human cardiac pathology.

Fischer TH, Herting J, Tirilomis T, Renner A, Neef S, Toischer K, Ellenberger D, Förster A, Schmitto JD, Gummert J, Schöndube FA, Hasenfuss G, Maier LS, Sossalla S.

Circulation. 2013 Aug 27;128(9):970-81. doi: 10.1161/CIRCULATIONAHA.113.001746. Epub 2013 Jul 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk